William V McCall1, Ruth M Benca1, Peter B Rosenquist1, Nagy A Youssef1, Laryssa McCloud1, Jill C Newman1, Doug Case1, Meredith E Rumble1, Steven T Szabo1, Marjorie Phillips1, Andrew D Krystal1. 1. Department of Psychiatry and Health Behavior, Medical College of Georgia at Augusta University (McCall, Rosenquist, Youssef, McCloud), and the Pharmacy Department, Augusta University Health (Phillips), Augusta, Ga.; Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine (Benca); Department of Medicine, Medical University of South Carolina, Charleston (Newman); Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, N.C. (Case); Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison (Rumble); Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, N.C. (Szabo, Krystal); Durham VA Health Care System, Durham, N.C. (Szabo); Langley Porter Psychiatric Hospital and Clinics and Department of Psychiatry, University of California, San Francisco, San Francisco (Krystal).
Abstract
OBJECTIVE: The authors sought to determine whether targeted treatment of insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia would provide a reduction in suicidal ideation superior to placebo. METHODS: Reducing Suicidal Ideation Through Insomnia Treatment was an 8-week three-site double-blind placebo-controlled parallel-group randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in conjunction with an open-label selective serotonin reuptake inhibitor. Participants were medication-free 18- to 65-year-olds with major depressive disorder, insomnia, and suicidal ideation. Suicidal ideation was the main outcome, measured first by the Scale for Suicide Ideation and second by the Columbia-Suicide Severity Rating Scale (C-SSRS). RESULTS:A total of 103 participants were randomly assigned to receive zolpidem-CR (N=51) or placebo (N=52) (64 women and 39 men; mean age=40.5 years). Zolpidem-CR had a robust anti-insomnia effect, especially in patients with the most severe insomnia symptoms. No significant treatment effect was observed on the Scale for Suicide Ideation (least squares mean estimate=-0.56, SE=0.83, 95% CI=-2.19, 1.08), but the reduction in scores was significantly positively related to improvement in insomnia after accounting for the effect of other depression symptoms. The C-SSRS indicated that zolpidem-CR had a significant treatment effect (least squares mean estimate=-0.26, SE=0.12, 95% CI=-0.50, -0.02). The advantage for zolpidem-CR in reducing suicidal ideation on the C-SSRS was greater in patients with more severe insomnia. No deaths or suicide attempts occurred. CONCLUSIONS: Although the results do not support the routine prescription of hypnotic medication for mitigating suicidal ideation in all depressed outpatients with insomnia, they suggest that coprescription of a hypnotic during initiation of an antidepressant may be beneficial in suicidal outpatients, especially in patients with severe insomnia.
RCT Entities:
OBJECTIVE: The authors sought to determine whether targeted treatment of insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia would provide a reduction in suicidal ideation superior to placebo. METHODS: Reducing Suicidal Ideation Through Insomnia Treatment was an 8-week three-site double-blind placebo-controlled parallel-group randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in conjunction with an open-label selective serotonin reuptake inhibitor. Participants were medication-free 18- to 65-year-olds with major depressive disorder, insomnia, and suicidal ideation. Suicidal ideation was the main outcome, measured first by the Scale for Suicide Ideation and second by the Columbia-Suicide Severity Rating Scale (C-SSRS). RESULTS: A total of 103 participants were randomly assigned to receive zolpidem-CR (N=51) or placebo (N=52) (64 women and 39 men; mean age=40.5 years). Zolpidem-CR had a robust anti-insomnia effect, especially in patients with the most severe insomnia symptoms. No significant treatment effect was observed on the Scale for Suicide Ideation (least squares mean estimate=-0.56, SE=0.83, 95% CI=-2.19, 1.08), but the reduction in scores was significantly positively related to improvement in insomnia after accounting for the effect of other depression symptoms. The C-SSRS indicated that zolpidem-CR had a significant treatment effect (least squares mean estimate=-0.26, SE=0.12, 95% CI=-0.50, -0.02). The advantage for zolpidem-CR in reducing suicidal ideation on the C-SSRS was greater in patients with more severe insomnia. No deaths or suicide attempts occurred. CONCLUSIONS: Although the results do not support the routine prescription of hypnotic medication for mitigating suicidal ideation in all depressed outpatients with insomnia, they suggest that coprescription of a hypnotic during initiation of an antidepressant may be beneficial in suicidal outpatients, especially in patients with severe insomnia.
Authors: William V McCall; Ruth M Benca; Meredith E Rumble; Doug Case; Peter B Rosenquist; Andrew D Krystal Journal: J Psychiatr Res Date: 2019-06-19 Impact factor: 4.791
Authors: W Vaughn McCall; Ruth M Benca; Peter B Rosenquist; Mary Anne Riley; Laryssa McCloud; Jill C Newman; Doug Case; Meredith Rumble; Andrew D Krystal Journal: Am J Psychiatry Date: 2016-09-09 Impact factor: 18.112
Authors: W Vaughn McCall; Nicholas Batson; Megan Webster; L Douglas Case; Indu Joshi; Todd Derreberry; Adam McDonough; Suzan R Farris Journal: J Clin Sleep Med Date: 2013-02-01 Impact factor: 4.062
Authors: Barry J Krakow; Dominic C Melendrez; Lisa G Johnston; James O Clark; Erin M Santana; Teddy D Warner; Michael A Hollifield; Ron Schrader; Brandy N Sisley; Samuel A Lee Journal: J Clin Psychiatry Date: 2002-08 Impact factor: 4.384
Authors: Andrew S Tubbs; Patricia Harrison-Monroe; Fabian-Xosé Fernandez; Michael L Perlis; Michael A Grandner Journal: J Clin Sleep Med Date: 2020-10-15 Impact factor: 4.062
Authors: Meredith E Rumble; William V McCall; Daniel A Dickson; Andrew D Krystal; Peter B Rosenquist; Ruth M Benca Journal: J Clin Sleep Med Date: 2020-08-15 Impact factor: 4.062
Authors: Jonathan S Emens; Alec M Berman; Saurabh S Thosar; Matthew P Butler; Sally A Roberts; Noal A Clemons; Maya X Herzig; Andrew W McHill; Miki Morimoto; Nicole P Bowles; Steven A Shea Journal: Psychiatry Res Date: 2020-08-04 Impact factor: 3.222